Skip to content
AnalystLens

Halozyme Therapeutics 8-K Report, Executive Changes (Apr 30, 2026)

Reports
Leadership Changes·Exhibits & Filings
Filing Date
Filed April 30, 2026
Period End
April 30, 2026
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Material agreement8-K · Nov ’19Nov ’19
  3. Leadership change8-K · Feb ’23Feb ’23
  4. Leadership change8-K · Mar ’25Mar ’25

Summary

Summary of the 8-K filed April 30, 2026. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced on April 30, 2026 that Darren Snellgrove has been appointed Chief Financial Officer, effective June 8, 2026, reporting to President and CEO Helen Torley.

Mr. Snellgrove, age 52, most recently served as Vice President, Investor Relations at Johnson & Johnson since May 2025, and previously served as CFO of J&J's Pharmaceutical sector from August 2021 to May 2025. David Ramsay, the current Interim CFO, will move to an advisory role effective June 8, 2026 to assist during a brief transition period. Compensation terms include an annual base salary of $670,000,a a bonus target of 50% of base salary (prorated in 2026), and a 2027 long-term incentive award with a minimum total grant date value of $4,000,000.

On joining, he will receive equity awards with a total grant date value of $7,200,000,b consisting of $3,200,000 in restricted stock units intended to make him whole for forfeited equity from J&J, vesting one-third annually over three years, and $4,000,000 in stock options. He will also receive a $350,000 sign-on cash bonus, partially subject to repayment if he leaves or is terminated for misconduct within 24 months.

The filing also includes a press release describing the new CFO's responsibilities, which include capital allocation, corporate development and investor relations, and the company's stated aim of accelerating shareholder value creation. The filing reports no family relationships with directors or executive officers and no material related-party interest.

Key Highlights

  1. Darren Snellgrove appointed CFO effective June 8, 2026, succeeding interim CFO David Ramsay, who will transition to an advisory role
  2. Mr. Snellgrove previously served as VP, Investor Relations at Johnson & Johnson (since May 2025) and as CFO of J&J's Pharmaceutical sector (August 2021 to May 2025)
  3. Base salary of $670,000 with a 50% bonus target, prorated in 2026
  4. Initial equity grants total $7,200,000: $3,200,000 in RSUs (make-whole, vesting over three years) and $4,000,000 in stock options
  5. Minimum 2027 long-term incentive award with a total grant date value of $4,000,000
  6. $350,000 sign-on cash bonus, partially repayable if he departs voluntarily or is terminated for misconduct within 24 months
  7. CFO responsibilities include capital allocation, corporate development and investor relations, reporting to CEO Helen Torley

Frequently Asked Questions

  1. When does the new CFO start, and what happens to the interim CFO?

    Darren Snellgrove's appointment is effective June 8, 2026. David Ramsay, the current Interim CFO, will assume an advisory role with the company as of that date to assist during a brief transition period.

  2. What is Darren Snellgrove's background?

    He is 52 years old and has served as Vice President, Investor Relations at Johnson & Johnson since May 2025. From August 2021 to May 2025 he was CFO of J&J's Pharmaceutical sector. Earlier roles at J&J included CFO, VP Finance and Operations Pharmaceutical R&D (2017 to August 2021) and CFO, J&J Innovation (2013 to 2017). He holds a B.A. Honors Degree in Economics and Philosophy from Southampton University and an M.B.A. from Villanova University.

  3. What is the compensation package for the new CFO?

    The package includes a $670,000 annual salary, a bonus target of 50% of base salary (prorated in 2026), a minimum 2027 long-term incentive award with a $4,000,000 grant date value, initial equity awards of $7,200,000 ($3,200,000 in RSUs and $4,000,000 in stock options), and a $350,000 sign-on cash bonus.

  4. Why were the RSUs and stock options structured as they were?

    The filing states the $3,200,000 RSU grant is intended to make Mr. Snellgrove whole for equity value forfeited on leaving J&J after 27 years of service. The balance is in stock options, which the filing says will deliver no value absent an increase in the share price after his start date, in line with the company's pay-for-performance philosophy.

  5. What responsibilities will the new CFO have?

    According to the accompanying press release, Mr. Snellgrove will lead Halozyme's financial operations and strategy, including capital allocation, corporate development and investor relations, and will report to President and CEO Helen Torley.